Historical note and terminology
Mitoxantrone was first approved in 1986 for the treatment of acute myelogenous leukemia. In 1996 it was approved to treat pain in patients with advanced hormone-refractory prostate cancer in combination with corticosteroids. In 1997, results of clinical trials were published, describing the potential of mitoxantrone in treating patients with progressive multiple sclerosis; it was approved by the Food and Drug Administration for this indication in 2000.
The content you are trying to view is available only to logged in, current MedLink Neurology subscribers.
If you are a subscriber, please log in.
If you are a former subscriber or have registered before, please log in first and then click select a Service Plan or contact Subscriber Services. Site license users, click the Site License Acces link on the Homepage at an authorized computer.